Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation
Status:
Active, not recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the safety and effectiveness of the WATCHMAN™ Left
Atrial Appendage Closure (LAAC) Device, including the post-implant medication regimen, for
subjects with non-valvular atrial fibrillation who are deemed not to be eligible for
anti-coagulation therapy to reduce the risk of stroke.